| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年6月 |
Digital Pathology Market – Global Forecast to 2029
本レポートは、製品、タイプ、用途、エンドユーザー、地域に基づいてデジタルパソロジー市場を分析しています。また、市場の成長に影響を与える要因（推進要因、機会、課題など）も分析しています。ステークホルダーにとっての市場機会と課題を評価し、市場リーダーの競争環境の詳細を提供します。さらに、ミクロ市場の成長傾向、見通し、そしてデジタルパソロジー市場全体への貢献についても調査しています。さらに、5つの主要地域における市場セグメントの収益予測も提供しています。
The market for digital pathology is segmented into three categories based on type: scanners, storage systems, and software. Given the significance of these devices in the digital pathology workflow, the scanners segment accounted for the largest share of the product category in 2024. Scanners are critical in enabling pathologists to view and analyze tissue samples on computer screens, as scanners convert physical glass slides to high-resolution digital images. The development of diagnostic remote access is paramount for improved accessibility and efficiency of pathology services by allowing pathologists to evaluate cases from any physical location, hence, the demand for scanners. The advancements in scanner technology, such as improved scanning rates and greater resolution imaging, have led to increased workflow, improved diagnostic accuracy, and value for investment for laboratories or medical facilities.
デジタルパソロジーの市場は、タイプに基づいてスキャナー、ストレージシステム、およびソフトウェアの3つのカテゴリに分類されます。デジタルパソロジーのワークフローにおけるこれらのデバイスの重要性を考えると、スキャナーセグメントは2024年に製品カテゴリで最大のシェアを占めました。スキャナーは、物理的なガラススライドを高解像度のデジタル画像に変換するため、病理学者がコンピューター画面で組織サンプルを表示および分析できるようにするために不可欠です。診断リモートアクセスの開発は、病理学者が物理的な場所から症例を評価できるようにすることで、病理学サービスのアクセス性と効率性を向上させるために最も重要であり、これがスキャナーの需要です。スキャン速度の向上や画像解像度の向上などのスキャナー技術の進歩は、ワークフローの増加、診断精度の向上、および研究室や医療施設の投資価値につながっています。
List of Companies Profiled in the Report
Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), and Kanteron Systems (Spain)
This report also includes.
- Analysis of key drivers (Growing adoption of AI-enabled digital pathology, rising burden of cancer, diabetes, and chronic diseases, expansion of digital pathology in drug discovery and biomarker validation, Cancer screening programs in emerging markets), restraints (High initial capital costs, Data interoperability issues with existing lab systems, regulatory and reimbursement uncertainty), opportunities (Affordable scanner development for low-resource settings, growing preference for personalized medicine, government-backed digitization in emerging economies) challenges (Shortage of skilled pathologists and technicians, algorithm validation issues, data security and patient privacy concerns), are contributing the growth of the digital pathology market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the digital pathology market
- Market Development: Comprehensive information about lucrative markets and analysis of the authentication and brand protection market across varied regions
- Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the digital pathology market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global digital pathology market